×
About 61,600 results

ALLMedicine™ Squamous Cell Carcinoma Center

Research & Reviews  22,892 results

Family History of Cancer is associated with poorer prognosis in Oral Squamous Cell Carc...
https://doi.org/10.1111/odi.14253
Oral Diseases; Xiao R, Wu J et. al.

May 18th, 2022 - The purpose of this study was to investigate the prognostic value of the family history of cancer (FHC) in predicting survival and clinicopathological features in oral squamous cell carcinoma (OSCC) patients. This single-institution study utilized...

Impact of Nodal Metastases in HPV-negative Oropharyngeal Cancer.
https://doi.org/10.1158/1055-9965.EPI-21-0776
Cancer Epidemiology, Biomarkers & Prevention : a Publicat... Chang CM, Chen MM et. al.

May 18th, 2022 - The updated American Joint Committee on Cancer (AJCC) 8th Edition staging manual restructured nodal classification and staging by placing less prognostic emphasis on nodal metastases for HPV-positive oropharyngeal squamous cell carcinoma (OPSCC). ...

N7-methylguanosine (m7G) tRNA modification: a novel autophagy modulator in cancer.
https://doi.org/10.1080/15548627.2022.2077551
Autophagy Han H, Zheng S et. al.

May 17th, 2022 - Macroautophagy/autophagy, a physiological process that is involved in tumorigenesis, is regulated at genetic and epigenetic levels. Emerging reports suggest that aberrant RNA modifications cause dysregulated autophagy and affect tumorigenesis, whi...

Potential role of interleukin-17 in the pathogenesis of oral lichen planus: A systemati...
https://doi.org/10.1111/jdv.18219
Journal of the European Academy of Dermatology and Venere... Husein-ElAhmed H, Steinhoff M

May 17th, 2022 - Oral lichen planus (OLP) is a chronic inflammatory mucocutaneous disease of unknown etiology, which may evolve into squamous cell carcinoma. Recent advances on OLP pathogenesis suggest the presence of Th17 cells and the up-regulation of interleuki...

Pretreatment Systemic Immune-Inflammation Index Can Predict Response to Neoadjuvant Che...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9092215
Pathology Oncology Research : POR; Liu P, Jiang Y et. al.

May 17th, 2022 - Background: The systemic immune-inflammation index (SII) has been identified as a predictor of chemotherapy efficacy for a variety of cancers, and we aimed to determine its ability to predict the response to chemotherapy and its long-term prognosi...

see more →

Guidelines  36 results

Clinical features, molecular characteristics and surgical management of primary penile ...
https://doi.org/10.1097/CMR.0000000000000788
Melanoma Research; Cakir OO, Pozzi E et. al.

Nov 30th, 2021 - Penile mucosal melanoma is an aggressive and rare genital malignancy. The aim of the present study was to review the management and outcomes of a homogenous cohort of patients with histologically confirmed penile mucosal melanoma, at a single spec...

Poor tumor differentiation is an independent adverse prognostic variable in patients wi...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8495291
Cancer Medicine; Lee LY, Lin CY et. al.

Sep 18th, 2021 - We sought to compare the prognostic impact of tumor differentiation with respect to adverse risk factors (RFs) identified by the National Comprehensive Cancer Network (NCCN) guidelines--including extranodal extension (ENE), positive/close margins,...

ACR Appropriateness Criteria® Staging and Follow-up of Vulvar Cancer.
https://doi.org/10.1016/j.jacr.2021.02.016
Journal of the American College of Radiology : JACR; , Lakhman Y et. al.

May 8th, 2021 - Vulvar cancer is an uncommon gynecologic tumor and one of several human papillomavirus-associated malignancies. Squamous cell carcinoma is the most prevalent histologic subtype of vulvar cancer, accounting for the majority of cases. Imaging plays ...

Summary of the updated 2020 guidelines for cutaneous squamous cell carcinoma.
https://doi.org/10.1111/ced.14587
Clinical and Experimental Dermatology; Woo WA, Suarez M-Falero B et. al.

Mar 18th, 2021 - Summary of the updated 2020 guidelines for cutaneous squamous cell carcinoma.|2021|Woo WA,Suarez M-Falero B,Keohane SG,|pathology,therapy,pathology,therapy,

Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ES...
https://doi.org/10.1016/j.annonc.2020.07.011
Annals of Oncology : Official Journal of the European Soc... Machiels JP, René Leemans C et. al.

Nov 27th, 2020 - Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up.|2020|Machiels JP,René Leemans C,Golusinski W,Grau C,Licitra L,|diagnosis,epidemiol...

see more →

Drugs  44 results see all →

Clinicaltrials.gov  641 results

The Oral Microbiome in OSCC
https://clinicaltrials.gov/ct2/show/NCT04925700

May 13th, 2022 - Previous work by a number of scientific teams has revealed that the types of bacteria that colonize the mouth differ between health and pre-cancerous or cancerous oral lesions. The purpose of this study is to investigate the extent of these change...

A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies
https://clinicaltrials.gov/ct2/show/NCT04923178

May 13th, 2022 - Background: Rare histological variants of the GU tract include bladder/urachal adenocarcinoma, squamous cell carcinoma, and small cell carcinoma; variants of urothelial carcinoma including plasmacytoid, sarcomatoid; renal tumors including sarcomat...

Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer
https://clinicaltrials.gov/ct2/show/NCT04847466

May 13th, 2022 - Background: Natural killer (NK) cells are an important component of an anti-tumor immune response. PD-L1 CAR-NK (PD-L1 t-haNKs) is an off the shelf, irradiated human, allogeneic, NK cell line that is frozen, shipped, thawed and then infused. PD-L1...

Study of INCA 0186 in Subjects With Advanced Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT04989387

May 13th, 2022 - This is an open-label, nonrandomized, multicenter, dose escalation, and dose expansion first-in human (FIH) Phase 1 study to determine the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of INCA00186 when given alone or in com...

Hearing Loss and the Effects of Statin Drugs in People With Head and Neck Squamous Cell Carcinoma Treated With Cisplatin Chemoradiation
https://clinicaltrials.gov/ct2/show/NCT03225157

May 13th, 2022 - Objectives: Primary: Determine whether head and neck cancer patients taking statin drugs for hyperlipidemia are at decreased risk of cisplatin-induced hearing loss. Secondary: Determine the incidence and severity of hearing loss in head and neck c...

see more →

News  1,009 results

Olson Grade, Need for More Treatment Are Markers of Increased Skin Cancer Risk in Actinic Keratoses
https://www.medscape.com/viewarticle/973526

May 6th, 2022 - NEW YORK (Reuters Health) - In patients with multiple actinic keratoses (AKs), Olson grade III and the need for more treatment were identified as markers for increased risk of cutaneous squamous cell carcinoma (cSCC) in a secondary analysis of a r...

Pembrolizumab With or Without Chemo Has Increased Efficacy With Increasing PD-L1 Expression in HNSCC
https://www.onclive.com/view/pembrolizumab-with-or-without-chemo-has-increased-efficacy-with-increasing-pd-l1-expression-in-hnscc

May 4th, 2022 - Pembrolizumab (Keytruda) with or without chemotherapy resulted in a numerically longer overall survival (OS) benefit vs cetuximab (Erbitux) plus chemotherapy in patients with head and neck squamous cell carcinoma (HNSCC) and a PD-L1 combined posit...

SOT101 Plus Pembrolizumab Elicits Encouraging Efficacy in Advanced Solid Tumors
https://www.onclive.com/view/sot101-plus-pembrolizumab-elicits-encouraging-efficacy-in-advanced-solid-tumors

May 2nd, 2022 - The addition of SOT101, an interleukin (IL)-2/IL-15 Rβγ superagonist, to Pembrolizumab (Keytruda) generated a clinical benefit and encouraging safety data in patients with advanced solid tumors, according to data presented at the 2022 AACR Annual ...

Extra COVID Jab for Cancer Patients; VA to Cover More Cancers; Cancer's Origin Story
https://www.medpagetoday.com/hematologyoncology/othercancers/98467

Apr 29th, 2022 - The National Comprehensive Cancer Network endorsed a second COVID mRNA booster for immunocompromised individuals, bringing the total to five jabs, as three is considered standard for someone who is immunocompromised. In a first-quarter earnings st...

Administration of RP1 Through Intratumoral Injection Offers Unique Advantages in Melanoma Treatment
https://www.onclive.com/view/administration-of-rp1-through-intratumoral-injection-offers-unique-advantages-in-melanoma-treatment

Apr 26th, 2022 - Oncolytic immunotherapy with talimogene laherparepvec (T-VEC; Imlygic) and vusolimogene oderparepvec (RP1) has the potential to provide unique clinical benefits in patients with melanoma through direct intratumoral administration, according to Nik...

see more →

Patient Education  18 results see all →